Moleculin Biotech Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	10.32	8.88	4.28	23.55	43.15	70.9
Cash & Short-Term Investments	10.32	8.88	4.28	23.55	43.15	70.9
Cash Growth	33.71%	107.53%	-81.83%	-45.42%	-39.15%	367.30%
Other Current Assets	0.64	0.81	0.92	2.72	2.45	1.59
Total Current Assets	10.96	9.69	5.19	26.27	45.6	72.5
Net Property, Plant & Equipment	0.35	0.39	0.58	0.8	0.68	0.45
Other Intangible Assets	11.15	11.15	11.15	11.15	11.15	11.15
Other Long-Term Assets	0.9	0.9	-	-	-	-
Total Assets	23.36	22.13	16.93	38.22	57.42	84.09
Accounts Payable	4.57	3.51	2.03	2.5	2.1	1.36
Accrued Expenses	3.39	3.35	3.33	4.32	2.72	2.26
Total Current Liabilities	7.96	6.85	5.36	6.82	4.82	3.62
Long-Term Leases	0.19	0.22	0.36	0.47	0.34	0.06
Other Long-Term Liabilities	0.03	0.04	-	4.86	0.08	1.41
Total Long-Term Liabilities	0.22	0.27	0.36	5.33	0.41	1.48
Total Liabilities	8.18	7.12	5.72	12.14	5.23	5.1
Common Stock	0.01	0	-	0.03	0.03	0.03
Additional Paid-in Capital	234.08	221	183.69	157.65	153.99	151.73
Accumulated Other Comprehensive Income	-0.05	0.01	-0.04	-0.01	0.01	0.04
Retained Earnings	-	-	-	-131.6	-101.84	-72.81
Total Common Shareholders' Equity	15.18	15.01	11.21	26.07	52.19	78.99
Shareholders' Equity	234.03	221.01	183.65	26.07	52.19	78.99
Total Liabilities & Equity	23.36	22.13	16.93	38.22	57.42	84.09
Total Debt	0.19	0.22	0.36	0.47	0.34	0.06
Net Cash (Debt)	10.13	8.66	3.92	23.08	42.81	70.84
Net Cash Growth	17.05%	120.82%	-83.01%	-46.10%	-39.57%	371.83%
Net Cash Per Share	4.78	7.31	28.46	292.01	561.23	988.43
Book Value	15.18	15.01	11.21	26.07	52.19	78.99
Book Value Per Share	7.16	12.67	81.38	329.94	684.22	1102.19
Tangible Book Value	4.04	3.86	0.06	14.93	41.04	67.85
Tangible Book Value Per Share	1.90	3.26	0.44	188.87	538.07	946.64

SEC Filings: 10-K · 10-Q